

## **RECEIPT**

## **GeneTether Therapeutics Inc.**

This is the receipt of the **British Columbia Securities Commission** for the **Amended and Restated Preliminary Long Form Prospectus** dated **January 27, 2022** (the amended preliminary prospectus) amending and restating the **Preliminary Long Form Prospectus** of the above Issuer dated **November 4, 2021**.

This receipt also evidences that the **Ontario Securities Commission** has issued a receipt for the amended preliminary prospectus.

The amended preliminary prospectus has been filed under Multilateral Instrument 11-102 *Passport System* in **Alberta.** A receipt for the amended preliminary prospectus is deemed to be issued by the regulator in this jurisdiction, if the conditions of the Instrument have been satisfied.

January 27, 2022

Larissa M. Streu

Larissa M. Streu Senior Legal Counsel, Corporate Finance

SEDAR Project Number 3296864